Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Argus Health
Johnson and Johnson
Express Scripts
Harvard Business School

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Pyridinyl-pyridines
Abstract:2-[R.sub.1 NHN(R)]-3-Q'-5-PY-6-Q-pyridines or pharmaceutically-acceptable acid-addition salts thereof are useful as cardiotonic agents, where Q is hydrogen or lower-alkyl, PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents, Q' is hydrogen or halo, R is hydrogen, lower-alkyl or lower-hydroxyalkyl, and R.sub.1 is hydrogen or when R is other than hydrogen R.sub.1 is the same as R. These compounds are prepared by reacting a 2-halo-3-Q'-5-PY-6-Q-pyridine with R.sub.1 NHNHR where 2-halo is bromo or chloro. Also shown are: the use of said 2-[R.sub.1 NN(R)]-3-Q'-5-PY-6-Q-pyridines as cardiotonic agents; and, the intermediates, 2,3-dihalo-5-PY-6-Q-pyridines, and their preparation from 3-nitro-5-PY-6-Q-2(1H)-pyridinones.
Inventor(s): Lesher; George Y. (Schodack, NY), Opalka, Jr.; Chester J. (Schodack, NY), Page; Donald F. (East Greenbush, NY)
Assignee: Sterling Drug Inc. (New York, NY)
Filing Date:Nov 02, 1981
Application Number:06/317,548
Claims:1. A 2,3-dihalo-5-PY-6-Q-pyridine having the formula ##STR3## or pharmaceutically-acceptable acid-addition salt thereof, where halo is chloro or bromo, PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents, and Q is hydrogen or lower-alkyl.

2. A compound according to claim 1 where halo is chloro, PY is 4-pyridinyl or 3-pyridinyl, and Q is hydrogen, methyl or ethyl.

3. The process which comprises reacting 3-nitro-5-PY-6-Q-2(1H)-pyridinone with a halogenating agent to produce 2,3-dihalo-5-PY-6-Q-pyridine according to claim 1 where halo is bromo or chloro, and PY and Q have the meanings given in claim 1.

4. The process according to claim 3 wherein halo is chloro, PY is 4-pyridinyl or 3-pyridinyl, and Q is hydrogen, methyl or ethyl.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: